Aldosterone

CinCor Pharma Announces Late-Breaking Presentation of Phase 2 BrigHtn Data on Baxdrostat in Treatment-Resistant Hypertension at the 2022 American Heart Association Scientific Sessions

Retrieved on: 
Monday, November 7, 2022
GLOBE, DBP, American College of Cardiology, Plasma, Renin, Death, Adult, M.D, U.S. Securities and Exchange Commission, AHA, CKD, Risk, American College, Plasma protein binding, Hypertension, Population, Conference call, Degenerative disease, SEC, Annual report, Cardiology, ID, Safety, Achievement, Time, Aldosterone, Hyponatremia, Conference, Patient, Urine, American Heart Association, Primary aldosteronism, Kidney, Hypotension, Potassium, Blood pressure, Kidney disease, SBP, Security (finance), COVID-19, Stroke, Phosphorus, Pharmaceutical industry, Collection

WALTHAM, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) announced the presentation today of Phase 2 data from its BrigHtn trial as part of the late-breaking science session at the 2022 American Heart Association (AHA) Scientific Sessions. Baxdrostat is a highly selective, once daily oral small molecule inhibitor of aldosterone synthase.

Key Points: 
  • Baxdrostat significantly decreases aldosterone in plasma and urine, while increasing plasma renin as a physiological compensatory change.
  • These changes in aldosterone and renin following treatment with baxdrostat reflect less salt exposure to the kidney and reduced blood pressure over time.
  • And, unlike earlier generations of aldosterone synthase inhibitors, serum cortisol levels were not reduced, once again confirming the highly selective mechanism of baxdrostat.
  • Though often asymptomatic, hypertension significantly increases the risk of heart disease, stroke, and kidney disease, amongst other diseases.

CinCor Pharma Announces Publication in the New England Journal of Medicine of Phase 2 BrigHtn Data on Selective Aldosterone Synthase Inhibitor Baxdrostat in Treatment-Resistant Hypertension

Retrieved on: 
Monday, November 7, 2022
GLOBE, American College of Cardiology, Renin, Death, Adult, M.D, U.S. Securities and Exchange Commission, The New England Journal of Medicine, CKD, Risk, American College, Plasma protein binding, Hypertension, Population, Degenerative disease, SEC, Annual report, Cardiology, Safety, Achievement, Time, Aldosterone, Patient, Primary aldosteronism, American Heart Association, Security (finance), Blood pressure, Kidney disease, COVID-19, Stroke, Pharmaceutical industry, Medicine, Collection

WALTHAM, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) announced that detailed results from the Phase 2 BrigHtn trial evaluating the safety and efficacy of baxdrostat in treatment-resistant hypertension were published online today in the New England Journal of Medicine. Baxdrostat is a highly selective, once daily oral small molecule inhibitor of aldosterone synthase.

Key Points: 
  • Baxdrostat is a highly selective, once daily oral small molecule inhibitor of aldosterone synthase.
  • The clinical biomarker activity of aldosterone and renin provide mechanistic insight into how baxdrostat achieves selective blood pressure lowering effects with no impact on cortisol.
  • CinCor, founded in 2018, is a clinical-stage biopharmaceutical company with a mission to bring innovation to the pharmaceutical treatment of cardio-renal diseases.
  • Its lead asset, baxdrostat (CIN-107), a highly selective, oral small molecule inhibitor of aldosterone synthase, is in clinical development for the treatment of hypertension and primary aldosteronism.

CinCor Pharma Appoints Michael W. Kalb, Executive Vice President and Chief Financial Officer

Retrieved on: 
Monday, November 7, 2022
CFO, American Heart Association, Disclosure, Company, Accounting, American College of Cardiology, Therapy, Amarin Corporation, Primary aldosteronism, Kidney disease, Time, American College, Cardiology, Risk, Degenerative disease, Certified Public Accountant, GLOBE, Hypertension, Population, Adult, Taro Pharmaceuticals, Ernst, Ernst & Young, COVID-19, LLP, Stroke, CKD, Death, Annual report, U.S. Securities and Exchange Commission, Aldosterone, Retirement, Security (finance), SEC, Achievement, Patient, Management, Pharmaceutical industry, Collection

WALTHAM, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (CinCor) announced the appointment of Michael W. Kalb as Executive Vice President and Chief Financial Officer (CFO), effective November 4.

Key Points: 
  • WALTHAM, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (CinCor) announced the appointment of Michael W. Kalb as Executive Vice President and Chief Financial Officer (CFO), effective November 4.
  • He is replacing Terry Coelho who is retiring from her role as Executive Vice President, CFO and Chief Business Development Officer.
  • Mr. Kalbs experience includes six years as Chief Financial Officer for Amarin Corporation, a publicly traded, multinational cardiovascular focused pharmaceutical company.
  • Prior to Amarin, he worked for seven years at Taro Pharmaceuticals where he was the Chief Financial Officer and Chief Accounting Officer.

Correcting and Replacing: CinCor Reports Third Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Friday, November 4, 2022
American Heart Association, Blood pressure, G&A, CINC, Society, OLE, Population, Adult, SBP, Income, Research, Research and development, Annual report, U.S. Securities and Exchange Commission, ET, CMC, Aldosterone, R, SEC, Administration, Disclosure, American College, MAD, Congress, GLOBE, International Society, Mercury (element), IPO, Death, Security (finance), Patient, Units of paper quantity, American College of Cardiology, Primary aldosteronism, Risk, ESC, European Society of Cardiology, COVID-19, Plasma protein binding, AHA, Chemistry, Kidney disease, Investment, Time, Publication, Degenerative disease, Safety, Stroke, CKD, ASN, American Society of Nephrology, ISH, NASDAQ, Achievement, Pharmaceutical industry, Collection, Hypertension, Cardiology

We are thrilled with the positive topline data reported for baxdrostat in treatment-resistant hypertension earlier this quarter.

Key Points: 
  • We are thrilled with the positive topline data reported for baxdrostat in treatment-resistant hypertension earlier this quarter.
  • We look forward to providing an update once the HALO trial data has been unblinded and analyzed, which is anticipated before year-end 2022.
  • In August 2022, CinCor reported positive topline data for the Phase 2 BrigHtn trial evaluating baxdrostat for patients with rHTN.
  • In October, CinCor announced the publication of the Phase 1 Multiple Ascending Dose Study Data in the journal, Hypertension Research.

CinCor Reports Third Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 3, 2022
American Heart Association, Blood pressure, G&A, CINC, Society, OLE, Population, Adult, SBP, Income, Research, Research and development, Annual report, U.S. Securities and Exchange Commission, CMC, Aldosterone, R, SEC, Administration, Disclosure, American College, MAD, Congress, GLOBE, International Society, Mercury (element), IPO, Death, Security (finance), Patient, Units of paper quantity, American College of Cardiology, Primary aldosteronism, Risk, ESC, European Society of Cardiology, COVID-19, Plasma protein binding, AHA, Chemistry, Kidney disease, Investment, Time, Publication, Degenerative disease, HALO, Safety, Stroke, CKD, ASN, American Society of Nephrology, ISH, NASDAQ, Achievement, Pharmaceutical industry, Collection, Hypertension, Cardiology

WALTHAM, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced financial results for the third quarter ended September 30, 2022 and provided a corporate update.

Key Points: 
  • We are thrilled with the positive topline data reported for baxdrostat in treatment-resistant hypertension earlier this quarter.
  • In August 2022, CinCor reported positive topline data for the Phase 2 BrigHtn trial evaluating baxdrostat for patients with rHTN.
  • In October, CinCor announced the publication of the Phase 1 Multiple Ascending Dose Study Data in the journal, Hypertension Research.
  • CinCor undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

CinCor Pharma Announces Presentation of Phase 1 Clinical Data for Baxdrostat at the Upcoming American Society of Nephrology Kidney Week 2022

Retrieved on: 
Tuesday, October 25, 2022
U.S. Securities and Exchange Commission, Time, ASN, Hypertension, Risk, SEC, Chronic kidney disease, Kidney, Population, Achievement, Stroke, Annual report, NASDAQ, Society, Cardiology, Patient, Degenerative disease, Primary aldosteronism, Security (finance), Aldosterone, American College of Cardiology, Kidney disease, Pharmacokinetics, Death, Adult, American Heart Association, Safety, CINC, GLOBE, American College, COVID-19, American Society of Nephrology, Pharmaceutical industry, Collection

WALTHAM, Mass., Oct. 25, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that the company will present Phase 1 clinical data on its lead product candidate, baxdrostat, as part of a poster presentation at the upcoming American Society of Nephrology (ASN) Kidney Week 2022 taking place November 3-6, 2022, in Orlando, Florida.

Key Points: 
  • WALTHAM, Mass., Oct. 25, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that the company will present Phase 1 clinical data on its lead product candidate, baxdrostat, as part of a poster presentation at the upcoming American Society of Nephrology (ASN) Kidney Week 2022 taking place November 3-6, 2022, in Orlando, Florida.
  • The presentation will include clinical data from a Phase 1 open-label trial assessing the safety and pharmacokinetics of baxdrostat in subjects with varying degrees of renal function.
  • Hypertension and chronic kidney disease are common comorbidities that are exacerbated by elevated aldosterone levels.
  • Baxdrostat is currently being evaluated in patients with uncontrolled hypertension and chronic kidney disease as part of the Phase 2 figHTN-CKD trial.

CinCor Pharma Announces Publication of Phase 1 Multiple Ascending Dose Study Data in Hypertension Research

Retrieved on: 
Friday, October 21, 2022
Time, Hypertension, Risk, SEC, Population, Achievement, Stroke, MAD, Annual report, NASDAQ, Patient, Degenerative disease, List of Nature Research journals, Primary aldosteronism, Aldosterone, Kidney disease, Pharmacokinetics, Death, Research, Adult, Safety, American Heart, CINC, GLOBE, Plasma, American College, Manuscript, COVID-19, Half-life, Pharmaceutical industry, Collection

WALTHAM, Mass., Oct. 21, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced the publication of Phase 1 clinical data for baxdrostat, a highly selective, once daily, oral small molecule inhibitor of aldosterone synthase, in the journal Hypertension Research.

Key Points: 
  • WALTHAM, Mass., Oct. 21, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced the publication of Phase 1 clinical data for baxdrostat, a highly selective, once daily, oral small molecule inhibitor of aldosterone synthase, in the journal Hypertension Research.
  • The publication includes clinical data from the companys randomized, Phase 1, placebo controlled multiple ascending dose (MAD) study evaluating the safety, pharmacokinetics, and pharmacodynamics of baxdrostat in healthy volunteers.
  • The dose-dependent reduction in plasma aldosterone and lack of impact on cortisol reinforce the selective blockade of aldosterone synthase by baxdrostat.
  • We believe these proof-of-concept data support further clinical advancement of this promising new treatment for hypertension, said Mason Freeman, M.D., Chief Medical Officer at CinCor.

Global Congenital Adrenal Hyperplasia Market Report to 2032 - Insights, Epidemiology and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Friday, October 14, 2022
Biotechnology, Pharmaceutical, Health, Androgen, Disease, 21-Hydroxylase, Review, Diagnosis, Infant, Congenital adrenal hyperplasia, Patient, CAH, Research, Enzyme, Adrenal crisis, Genetic distance, Aldosterone, Kidney, Congenital adrenal hyperplasia due to 21-hydroxylase deficiency, Mineralocorticoid, Awareness, Birth defect, Hormone, Death, Exocrine gland, Algorithm, Pharmaceutical industry

It covers the details of conventional and current medical therapies and diagnoses available in the congenital adrenal hyperplasia (CAH) market to treat the condition.

Key Points: 
  • It covers the details of conventional and current medical therapies and diagnoses available in the congenital adrenal hyperplasia (CAH) market to treat the condition.
  • The congenital adrenal hyperplasia (CAH) Market Report gives a thorough understanding of congenital adrenal hyperplasia (CAH) by including details of disease definition, symptoms, causes, pathophysiology, and diagnosis.
  • It also provides the treatment algorithms and treatment guidelines for congenital adrenal hyperplasia (CAH) in the US, Europe, and Japan.
  • The launch of emerging therapies will significantly impact the congenital adrenal hyperplasia (CAH) market.

CinCor Pharma Announces Oral Presentation of Phase 1 Data for Baxdrostat at the Upcoming 29th International Society of Hypertension 2022 Conference

Retrieved on: 
Wednesday, October 12, 2022
Risk, Population, Stroke, MAD, ISH, Collection, NASDAQ, Cardiology, Patient, Degenerative disease, Primary aldosteronism, Aldosterone, International Society, American College of Cardiology, Kidney disease, Doctor of Philosophy, Pharmacokinetics, Death, American Heart Association, Safety, Adult, CINC, GLOBE, Translation, American College, Pharmaceutical industry, Hypertension

WALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that the company will present Phase 1 clinical data on its lead product candidate, baxdrostat, as part of an oral presentation at the upcoming 29th International Society of Hypertension (ISH) 2022 conference taking place October 12-16, 2022 in Kyoto, Japan.

Key Points: 
  • WALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that the company will present Phase 1 clinical data on its lead product candidate, baxdrostat, as part of an oral presentation at the upcoming 29th International Society of Hypertension (ISH) 2022 conference taking place October 12-16, 2022 in Kyoto, Japan.
  • Baxdrostat is a highly selective, once daily, oral small molecule inhibitor of aldosterone synthase.
  • The presentation will include clinical data from the randomized, Phase 1, placebo controlled multiple ascending dose (MAD) study which evaluated the safety, pharmacokinetics, and pharmacodynamics of baxdrostat in healthy volunteers.
  • Its lead asset, baxdrostat, a highly selective, oral small molecule inhibitor of aldosterone synthase, is in clinical development for the treatment of hypertension and primary aldosteronism.

Primary Aldosteronism Foundation Announces Creation of Alliance to Drive Diagnosis and Treatment of Common Cause of Hypertension

Retrieved on: 
Wednesday, September 28, 2022
Consensus, Consensus decision-making, Time, Primary aldosteronism, Aldosterone, Knowledge, Company, Hypertension, Therapy, Patient, Disorder, Public health, Solution, Diagnosis, Foundation, Mitsubishi Tanabe Pharma, Adrenal insufficiency, Caregiver, Alliance, Research, Awareness, Disease, Pharmaceutical industry, Medicine

PHOENIX, Sept. 28, 2022 /PRNewswire/ -- The Primary Aldosteronism Foundation ("Foundation"), has announced today the creation of a multistakeholder alliance to drive diagnosis and treatment of primary aldosteronism, a common cause of hypertension.

Key Points: 
  • PHOENIX, Sept. 28, 2022 /PRNewswire/ -- The Primary Aldosteronism Foundation ("Foundation"), has announced today the creation of a multistakeholder alliance to drive diagnosis and treatment of primary aldosteronism, a common cause of hypertension.
  • The initiative will facilitate the design and implementation of interventions to advance standards of care for primary aldosteronism, a highly prevalent adrenal disease and common cause of hypertension.
  • Primary aldosteronism is neither diagnosed nor treated 95 percent of the time despite causing significant cardiovascular and renal damage along with systemic inflammation.
  • Together with the Foundation, we hope to address the standards of care for hypertension and primary aldosteronism and support its commitment to hypertension prescribers, patients and caregivers."